Navigation Links
Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company
Date:12/16/2009

alignant) tumors involving single as well as repeated intravenous administration. Atu027 specifically targets PKN3, a molecule involved in cancer growth and metastasis formation. Atu027 is Silence's most advanced clinical candidate for a systemically delivered siRNA using the Company's proprietary AtuPLEX delivery technology.

In March 2008 Silence Therapeutics announced a collaboration with AstraZeneca (LSE: AZN) focused on the development of a range of novel delivery approaches for siRNA molecules. Under the terms of the agreement both Silence Therapeutics and AstraZeneca will be allowed to commercialize the truly novel delivery systems that the two partners develop together.

Silence Therapeutics has granted a license to AstraZeneca to develop novel AtuRNAi therapeutics against five specific targets. This collaboration was the first industry validation of the potential application of Silence Therapeutics' proprietary AtuRNAi molecules and solidified the Company's leadership position in field of RNAi therapeutics.

The Company's AtuRNAi technology also has been sublicensed to Pfizer via Quark's license to it of the compound RTP-801i-14 for the treatment of age-related macular degeneration (AMD) and a number of other indications. This compound entered a phase II clinical study in July 2008. Silence Therapeutics also has licensed to Quark rights to the AtuRNAi structure for Quark's proprietary compound, AKIi-5 and DGFi, which are both in Phase I human clinical studies for treatment of acute kidney injury and delayed graft function in kidney transplantation respectively.

Silence Therapeutics is based in London, UK, and Berlin, Germany, and is listed on AIM.

About Intradigm

Intradigm is a private biotechnology company committed to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases with an initial focus on oncolog
'/>"/>

SOURCE Intradigm Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Actress and New Mom Keri Russell Joins PKIDs to launch Silence the Sounds of Pertussis Campaign
2. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
3. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
4. Silence Therapeutics Announces Board Changes
5. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
11. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Foundation today announced it has established a relief fund ... weather that has gripped much of the nation. AARP and ... to support these emergency relief efforts AARP and AARP Foundation ... up to $500,000 in aid. The matching program will be ...
(Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  ... Award" from the Journal of Drugs in Dermatology ... Clinical Conference (ODAC). The event is January 17-20, 2014, at the ... . The ODAC is a ...
(Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, Inc. (OTC ... U.S. provisional patent application concerning composition of matter, biological ... targeted tumor cell death.  This patent ... double stranded RNA molecules (VSRNAs) which interfere with the ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
(Date:4/18/2014)... April 18, 2014) Benaroya Research Institute at ... how blocking a particular molecule in metastatic breast cancer ... number of lung metastases. BRI scientists have found in ... shrink tumors by 60 - 80 percent and can ... lung. The $1.8 million five-year grant comes from the ...
(Date:4/17/2014)... inflammation in benign prostate tissue was associated with ... was found even in those with low prostate-specific ... in Cancer Epidemiology, Biomarkers & Prevention , ... Research. , An analysis of prostate tissue biopsies ... of the Prostate Cancer Prevention Trial (PCPT) found ...
(Date:4/17/2014)... today in PLOS Pathogens , children who live ... can mount an immune response to infection with malaria ... of high fever and illness and partially control the ... may help researchers develop future interventions that prevent or ... Each year, approximately 200 million cases of malaria occur ...
(Date:4/17/2014)... Jon McCullers, MD, was recently invited to submit ... Nature Reviews Microbiology , one of the world,s ... infectious disease specialist, and chair of the Department ... Science Center, analyzed the epidemiology and microbiology of ... as well as more recent 2009 novel H1N1 ...
(Date:4/17/2014)... The cause of neuronal death in Parkinson,s disease is ... may be mistaken for foreign invaders and killed by ... autoimmune diseases like type I diabetes, celiac disease, and ... published April 16, 2014, in Nature Communications . ... in Parkinson,s disease; but if true, it could lead ...
Breaking Medicine News(10 mins):Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Is Parkinson's an autoimmune disease? 2
... Move Policymakers to "Thoughtful Dialogue"WASHINGTON, Feb. 11 ... the merits of the Medicare Durable Medical Equipment, ... home oxygen leaders call on legislators to carefully ... on beneficiary services and much needed service-oriented jobs. ...
... COLUMBIA, S.C., Feb. 11 The Consortium for ... business, academic and economic development organizations intended to ... board and named Lonnie Emard as the interim ... information systems at BlueCross BlueShield of South Carolina, ...
... all-digital cancer hospital enhances commitment to quality care ... Feb. 11 Cancer Treatment Centers of America ... hospital in Goodyear, Ariz. The 213,000-square-foot facility is ... network. CTCA at Western Regional Medical Center ...
... St George,s, University of London measured recent exposure to tobacco ... Regional Heart Study by measuring the levels of cotinine - ... points 20 years apart. A blood cotinine level above 0.7ng/mL ... a heart attack (2), and other studies have suggested that ...
... 2009 "The House of Representatives and the Senate ... payment, on health care reform in the economic stimulus ... American College of Physicians, said today. ... that will provide adequate funding for critical health care ...
... Feb. 11 Z Trim Holdings,(OTC Bulletin Board: ZTHO), ... Valley,s E.D. Smith "Garden Goodness",French Style Dressing is made ... panel. , E.D. Smith, a ... being,the #1 store brand supplier of pourable dressings in ...
Cached Medicine News:Health News:As Congress Debates Competitive Bidding Program, Home Oxygen Beneficiaries and Providers Left to Cope with 27 Percent Cut to Medicare Home Oxygen Benefit 2Health News:S.C.-Based Technology Consortium Names Interim Executive Director and Board 2Health News:S.C.-Based Technology Consortium Names Interim Executive Director and Board 3Health News:Electronic Health Record Advances Patient-Centered Cancer Care 2Health News:Electronic Health Record Advances Patient-Centered Cancer Care 3Health News:Smokers putting their loved ones at risk of heart attacks 2Health News:ACP commends Congress for including health care reform in economic stimulus legislation 2Health News:Bay Valley's French Style Dressing Demonstrates Z Trim's Value to Private Label and Store Brands 2Health News:Bay Valley's French Style Dressing Demonstrates Z Trim's Value to Private Label and Store Brands 3Health News:Bay Valley's French Style Dressing Demonstrates Z Trim's Value to Private Label and Store Brands 4
... The Vasculight VS system improves the ... (sun-induced freckles), most benign brown pigments, telangiectasias, ... of Intense Pulsed Light (IPLTM) treats pigmentary ... The unique, combined approach of IPL and ...
... The new IPL Quantum DL ... technology with the reliability and simplicity ... Its modular and upgradeable design protects ... the SR mode for IPL skin ...
Available in Purple, orange, dark blue, yellow, gray, royal blue, green and light blue colors....
Each jet black lens features a mesmerizing thin white line that spirals toward the center of the pupil....
Medicine Products: